Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S–12S.
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216–223.
Rubin LJ. Primary pulmonary hypertension (review). N Engl J Med 1997;336:111–117.
Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Bégaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996:335;609–616.
Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection Chest 1991;100:1268–1271.
Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000;9:338–342.
Humbert M, Sitbon O, Chaouat Ari, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France. Registry from a national Registry. J Respir Crit Care Med 2006;173:1023–1030.
Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997:337; 581–588.
Otterdal K, Andreassen AK, Yndestad A, Oie E, Sandberg WJ, Dahl CP, Pedersen TM, Ueland T, Gullestad L, Brosstad FR, Aukrust P, Damås JK. Raised LIGHT levels in pulmonary artery hypertension. Am J Respir Crit Care Med 2008;177:202–207.
Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1884;70:580–587.
Sitbon O. Prevalence of HIV-related pulmonary artery hypertension in the current antiretro-viral therapy era. Am J Respir Crit Care Med 2008;177:108–113.
Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989–993.
Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344–350.
Kanemoto N, Sasamoto H. Pulmonary hemodynamics in primary pulmonary hypertension. Jpn Heart J 1979;20:395–405.
Eysmann SB, Palevsky HI, Reichek N, Hackney K, Douglas PS. Two dimensional and Doppler-echocardiographic correlates of survival in primary pulmonary hypertension. Circulation 1989;80:353–360.
Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35:765–770.
Nagaya N, Ando M, Oya H, Ohkita Y, Kyotani S, Sakamaki F, Nakanishi N. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterec-tomy. Ann Thorac Surg 2002;74:180–184.
Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, Hoeffken G. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120:1562–1569.
Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, Yamagishi M, Kunieda T, Miyatake K. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999;160:487–492.
Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000;37:741–745.
Goodman DJ, Harrison DC, Popp RL. Echocardiographic features of primary pulmonary hypertension. Am J Cardiol 1974;33:438–443.
Moser KM, Page GT, Ashburn WL, Fedullo PF. Perfusion lung scans provide a guide to which patients with apparent primary pulmonary hypertension merit angiography. West J Med 1988;148:167–170.
Child JS, Wolfe JD, Tashkin D, Nakano R. Fatal lung scan in a case of pulmonary hypertension due to obliterative pulmonary vascular disease. Chest 1975;67:308–310.
Rubin LJ. Primary pulmonary hypertension: ACCP consensus statement. Chest 1993;104: 236–250.
Badesch DB, Abman SH, Ahearn GS, et al. American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 Suppl):35S–62S.
Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917–1928.
Wagenvoort CA, Mulder PG. Thrombotic lesions in primary plexigenic arteriopathy. Chest 1993:103;844–849.
Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Histopathology of primary pulmonary hypertension. Circulation 1989;80:1198–206.
Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990;82:841–847.
Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81.
Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Hervé P, Simonneau G. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105–3111.
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al. A comparison of continuous intravenous epoprostenol (pros-tacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996:334;296–302.
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, Simonneau G.Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780–788.
McLaughlin V V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477–1482.
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G.Bosentan therapy for pulmonary arterial hypertension (erratum in: N Engl J Med 2002;346:1258). N Engl J Med. 2002;21;346:896–903.
Rosentzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH, Morganti A, Nguyen N, Barst RJ. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005;60:1025–1030.
Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48–54.
Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.Eur Respir J 2004;24:353–359.
Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N; STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049–2056.
Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenalafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148–2157.
Sandoval J, Barst RJ, Rich S, Rothman A. Atrial septostomy for pulmonary hypertension. In: Rich S, editor. Primary pulmonary hypertension:e summary from the World Symposium on PPH 1998. Available at: http://www.Who.int/ncd/cvd/pph.html
Pasque MK, Trulock EP, Cooper JD, Triantafillou AN, Huddleston CB, Rosenbloom M, Sundaresan S, Cox JL, Patterson GA. Single lung transplantation for pulmonary hypertension. Circulation 1995;92:2252–2258.
2001 Annual report of U.S. organ procurement and transplantation network and the scientific registry of transplant recipients: transplant data 1991–2000. Department of Health and Human Services, Health Resource and Service Administration Office of Special Programs, Division of transplantation, Rockville, MD; United Network for organ sharing; Richmond VA ; University Renal Research and Education Association, Ann Arbor, MI.
Hertz MI, Taylor DO, Trulock EP, Boucek MM, Mohacsi PJ, Edwards LB, Keck BM. The registry of the International Society for Heart and Lung Transplantation: Nineteenth Official Report. J Heart Lung Transplant 2002;21:950–970.
Acknowledgments
We thank Ivano Cantore for expert technical designer assistance and for help in the production of the figures.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Carbone, R.G., Bottino, G. (2009). Primary Pulmonary Hypertension. In: Baughman, R.P., Carbone, R.G., Bottino, G. (eds) Pulmonary Arterial Hypertension and Interstitial Lung Diseases. Humana Press. https://doi.org/10.1007/978-1-60327-074-8_5
Download citation
DOI: https://doi.org/10.1007/978-1-60327-074-8_5
Publisher Name: Humana Press
Print ISBN: 978-1-58829-695-5
Online ISBN: 978-1-60327-074-8
eBook Packages: MedicineMedicine (R0)